AKR7A2 polyclonal antibody

O43488

Catalyzes the NADPH-dependent reduction of succinic semialdehyde to gamma-hydroxybutyrate. May have an important role in producing the neuromodulator gamma-hydroxybutyrate (GHB). Has broad substrate specificity. Has NADPH-dependent aldehyde reductase activity towards 2-carboxybenzaldehyde, 2-nitrobenzaldehyde and pyridine-2-aldehyde (in vitro). Can reduce 1, 2-naphthoquinone and 9, 10-phenanthrenequinone (in vitro). Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

AKR7A2 pAb detects endogenous levels of AKR7A2 protein.

Immunohistochemistry (IHC) analysis of AKR7A2 polyclonal antibody in paraffin-embedded Human Kidney Cancer tissue.

For research use only, not for use in diagnostic procedure.

Recombinant full length Human AKR7A2.